Inhibrx Biosciences

Recent news

• Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325
  Market Newswire · 2026/8/21
• Rating change
  Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $300
  Market Newswire · 2026/4/22
• Analysts Offer Insights on NA Companies: Evommune, Inc. (EVMN), Inhibrx Biosciences Inc (INBX) and Circle Internet Group, Inc. Class A (CRCL)
  TipRanks · 2026/9/9
• LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230
  Market Newswire · 2026/9/8
• Rating change
  Stifel Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $150
  Market Newswire · 2026/4/17
• Rating change
  JMP Securities Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
  Market Newswire · 2025/3/19
• H.C. Wainwright Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $245
  Market Newswire · 2026/9/9
• Rating change
  LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $230
  Market Newswire · 2026/5/11
• Rating change
  LifeSci Capital Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $200
  Market Newswire · 2026/4/24
• Company notice
  Inhibrx: Inhibrx, Inc. - Distribution Option Symbol: INBX New Symbol: INBX1
  OCC · 2024/5/30
• Rating change
  LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $200
  Market Newswire · 2026/4/26
• Rating change
  Citizens JMP Maintains Inhibrx Biosciences(INBX.US) With Hold Rating
  Market Newswire · 2025/5/16
• Rating change
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Fractyl Health, Inc. (GUTS) and Inhibrx Biosciences Inc (INBX)
  TipRanks · 2026/5/11
• Rating change
  Analysts Are Bullish on These Healthcare Stocks: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Inhibrx (INBX)
  TipRanks · 2023/11/20
• H.C. Wainwright Initiates Inhibrx Biosciences(INBX.US) With Buy Rating, Announces Target Price $245
  Market Newswire · 2026/8/25
• Rating change
  Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Raises Target Price to $325
  Market Newswire · 2026/5/15

Headlines are aggregated automatically and are not independently verified or edited by our team.